SuperworthOutset Medical EPS OM
Diluted earnings per share by quarter and over the last twelve months, from 2019.
- Last 12 months, to Jun 30, 2026
- −$4.08
- Latest quarter, Q2 FY26
- −$0.97
- Fiscal year 2025
- −$6.78
Outset Medical's earnings per share was −$4.08 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.97.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$6.78 | n/a |
| FY2024 | −$37.04 | n/a |
| FY2023 | −$52.50 | n/a |
| FY2022 | −$50.85 | n/a |
| FY2021 | −$44.40 | n/a |
| FY2020 | −$120.45 | n/a |
| FY2019 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.97 | n/a | −$4.08 | |
| Q1 FY26 | −$1.03 | n/a | −$4.15 | |
| Q4 FY25 | −$1.08 | n/a | −$6.78 | |
| Q3 FY25 | −$1.00 | n/a | −$12.99 | |
| Q2 FY25 | −$1.04 | n/a | −$20.01 | |
| Q1 FY25 | −$3.66 | n/a | −$28.93 | |
| Q4 FY24 | −$7.29 | n/a | −$37.04 | |
| Q3 FY24 | −$8.02 | n/a | −$41.30 | |
| Q2 FY24 | −$9.96 | n/a | −$47.23 | |
| Q1 FY24 | −$11.77 | n/a | −$50.77 | |
| Q4 FY23 | −$11.55 | n/a | −$52.50 | |
| Q3 FY23 | −$13.95 | n/a | −$53.55 |
Against its peers
Companies in Healthcare nearest Outset Medical's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| OMOutset Medical | −$4.08 | |
| LFVNLifevantage | $0.40 | −46% a year |
| SPROSpero Therapeutics | $0.11 | |
| ICCCImmucell | $0.08 | −58% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| NEPHNephros | $0.16 | +33% a year |
| PDEXPro DEX | $4.11 | +52% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| Peer median | $0.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Outset Medical
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.